Burning Rock Biotech Limited(BNR)Earnings, Financials & Key Ratios
BNR•NASDAQ
Price updated Jun 24, 2026
AboutBurning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.Show more
- Revenue$540M+4.6%
- EBITDA-$33M+89.2%
- Net Income-$55M+84.0%
- EPS (Diluted)-49.60-47.3%
- Gross Margin74.67%+6.3%
- EBITDA Margin-6.13%+89.6%
- Operating Margin-10.16%+85.3%
- Net Margin-10.26%+84.7%
- ROE-9.91%+80.7%
BNR Key Insights
Burning Rock Biotech Limited (BNR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y profit CAGR of 32.9%
- ✓Strong Piotroski F-Score: 7/9
- ✓Share count reduced 89.5% through buybacks
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BNR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BNR Price & Volume
Burning Rock Biotech Limited (BNR) stock price & volume — 10-year historical chart
Loading chart...
BNR Growth Metrics
Burning Rock Biotech Limited (BNR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years4.65%
3 Years-1.42%
TTM4.6%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM84.03%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM84.63%
Return on Capital
10 Years-46.23%
5 Years-45.89%
3 Years-43%
Last Year-9.2%
BNR Recent Earnings
Burning Rock Biotech Limited (BNR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (88%)●Beat Revenue 2/12 qtrs (50%)
Q3 2026Latest
Jun 9, 2026Metric
Actual
Est
EPS
$0.20+91.3%
$2.29
Rev
$16M-18.3%
$19M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.21+85.0%
$1.40
Rev
$18M
—
Q4 2025
Nov 20, 2025Metric
Actual
Est
EPS
$0.26
—
Rev
$18M
—
Q4 2025
Sep 8, 2025Metric
Actual
Est
EPS
$0.15
—
Rev
$21M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 9, 2026 | $0.20vs $2.29+91.3% | $16Mvs $19M-18.3% |
| Q2 2026 | Mar 12, 2026 | $0.21vs $1.40+85.0% | $18M |
| Q4 2025 | Nov 20, 2025 | $0.26 | $18M |
| Q4 2025 | Sep 8, 2025 | $0.15 | $21M |
Based on last 12 quarters of dataView full earnings history →
BNR Peer Comparison
Burning Rock Biotech Limited (BNR) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 GH | 18.16B | 136.96 | -41.25 | 32.88% | -40.1% | |||
 NTRA | 37.23B | 259.97 | -171.03 | 35.9% | -9.05% | -15.13% | 0.13 | |
 ACMR | 6.73B | 101.60 | 74.16 | 15.24% | 9.48% | 5.13% | 0.16 | |
 ILMN | 26.6B | 175.09 | 32.13 | -0.78% | 19.43% | 32.84% | 0.94 | |
 TMO | 182.91B | 492.20 | 27.75 | 3.91% | 15.18% | 13.23% | 0.76 | |
 PACB | 447.27M | 1.44 | -0.79 | 3.89% | -80.34% | -488.45% | 141.98 | |
 FGBI | 173.86M | 10.56 | -2.53 | -19.95% | -21.78% | -20.17% | 0.82 |
Compare BNR vs Peers
Burning Rock Biotech Limited (BNR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BNR Income Statement
Burning Rock Biotech Limited (BNR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 111.17M | 208.87M | 381.68M | 429.9M | 507.86M | 563.24M | 537.43M | 515.82M | 539.57M |
Revenue Growth % | - | 87.89% | 82.74% | 12.64% | 18.13% | 10.9% | -4.58% | -4.02% | 4.6% |
Cost of Goods Sold | 39.47M | 73.81M | 108.34M | 115.98M | 143.72M | 183.2M | 174.21M | 153.42M | 136.65M |
COGS % of Revenue | 35.51% | 35.34% | 28.39% | 26.98% | 28.3% | 32.53% | 32.41% | 29.74% | 25.33% |
Gross Profit | 71.7M▲ 0% | 135.06M▲ 88.4% | 273.33M▲ 102.4% | 313.92M▲ 14.8% | 364.15M▲ 16.0% | 380.04M▲ 4.4% | 363.23M▼ 4.4% | 362.4M▼ 0.2% | 402.91M▲ 11.2% |
Gross Margin % | 64.49% | 64.66% | 71.61% | 73.02% | 71.7% | 67.47% | 67.59% | 70.26% | 74.67% |
Gross Profit Growth % | - | 88.38% | 102.38% | 14.85% | 16% | 4.36% | -4.42% | -0.23% | 11.18% |
Operating Expenses | 192.56M | 296.45M | 442.43M | 726.33M | 1.16B | 1.36B | 1.03B | 719.96M | 457.76M |
OpEx % of Revenue | 173.22% | 141.93% | 115.92% | 168.95% | 228.65% | 241.54% | 192.13% | 139.58% | 84.84% |
Selling, General & Admin | 143.54M | 191.16M | 285.49M | 462.39M | 793.35M | 938.58M | 685.53M | 452.54M | 291.26M |
SG&A % of Revenue | 129.12% | 91.52% | 74.8% | 107.56% | 156.21% | 166.64% | 127.56% | 87.73% | 53.98% |
Research & Development | 49.02M | 105.3M | 156.94M | 263.94M | 367.86M | 421.87M | 347.02M | 232.29M | 166.49M |
R&D % of Revenue | 44.1% | 50.41% | 41.12% | 61.4% | 72.43% | 74.9% | 64.57% | 45.03% | 30.86% |
Other Operating Expenses | -32K | -488K | 0 | 0 | 0 | 0 | 0 | 35.13M | 0 |
Operating Income | -120.87M▲ 0% | -161.4M▼ 33.5% | -169.09M▼ 4.8% | -412.4M▼ 143.9% | -797.06M▼ 93.3% | -980.41M▼ 23.0% | -669.32M▲ 31.7% | -357.56M▲ 46.6% | -54.84M▲ 84.7% |
Operating Margin % | -108.73% | -77.27% | -44.3% | -95.93% | -156.94% | -174.07% | -124.54% | -69.32% | -10.16% |
Operating Income Growth % | - | -33.53% | -4.77% | -143.89% | -93.27% | -23% | 31.73% | 46.58% | 84.66% |
EBITDA | -99.55M | -136.72M | -137.73M | -379.1M | -749.3M | -856.31M | -535.92M | -305.36M | -33.08M |
EBITDA Margin % | -89.55% | -65.46% | -36.09% | -88.18% | -147.54% | -152.03% | -99.72% | -59.2% | -6.13% |
EBITDA Growth % | - | -37.33% | -0.74% | -175.24% | -97.65% | -14.28% | 37.42% | 43.02% | 89.17% |
D&A (Non-Cash Add-back) | 21.31M | 24.68M | 31.36M | 33.31M | 47.77M | 124.1M | 133.4M | 52.2M | 21.76M |
EBIT | -120.87M | -159.55M | -160.17M | -406.57M | -794.26M | -969.25M | -651.3M | -322.43M | -53.76M |
Net Interest Income | -9.86M | -16.61M | 2.17M | 5.4M | 1.92M | 9.46M | 17.96M | 12.21M | 8.02M |
Interest Income | 0 | 1.34M | 11.16M | 6.07M | 3.46M | 9.46M | 17.96M | 12.21M | 8.05M |
Interest Expense | 9.86M | 17.95M | 8.99M | 667K | 1.54M | 0 | 0 | 0 | 30K |
Other Income/Expense | -10.41M | -16.1M | -64K | 5.17M | 1.27M | 11.16M | 18.02M | 16.82M | 1.05M |
Pretax Income | -131.28M▲ 0% | -177.5M▼ 35.2% | -169.16M▲ 4.7% | -407.24M▼ 140.7% | -795.8M▼ 95.4% | -969.25M▼ 21.8% | -651.3M▲ 32.8% | -340.74M▲ 47.7% | -53.79M▲ 84.2% |
Pretax Margin % | -118.09% | -84.98% | -44.32% | -94.73% | -156.7% | -172.09% | -121.19% | -66.06% | -9.97% |
Income Tax | 0 | 0 | 0 | 0 | 899K | 1.99M | 2.39M | 5.88M | 1.56M |
Effective Tax Rate % | 0% | 0% | 0% | 0% | -0.11% | -0.2% | -0.37% | -1.73% | -2.89% |
Net Income | -131.28M▲ 0% | -177.5M▼ 35.2% | -168.34M▲ 5.2% | -407.24M▼ 141.9% | -796.7M▼ 95.6% | -971.23M▼ 21.9% | -653.69M▲ 32.7% | -346.63M▲ 47.0% | -55.35M▲ 84.0% |
Net Margin % | -118.09% | -84.98% | -44.1% | -94.73% | -156.87% | -172.44% | -121.63% | -67.2% | -10.26% |
Net Income Growth % | - | -35.21% | 5.16% | -141.92% | -95.64% | -21.91% | 32.69% | 46.97% | 84.03% |
Net Income (Continuing) | -131.28M | -177.5M | -169.16M | -407.24M | -796.7M | -971.23M | -653.69M | -346.63M | -55.35M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -102.02▲ 0% | -103.82▼ 1.8% | -142.30▼ 37.1% | -68.76▲ 51.7% | -76.45▼ 11.2% | -93.47▼ 22.3% | -63.84▲ 31.7% | -33.67▲ 47.3% | -49.60▼ 47.3% |
EPS Growth % | - | -1.76% | -37.06% | 51.68% | -11.18% | -22.26% | 31.7% | 47.26% | -47.31% |
EPS (Basic) | -102.02 | -103.82 | -142.30 | -68.76 | -76.45 | -93.47 | -63.84 | -33.67 | -49.60 |
Diluted Shares Outstanding | 1.81M | 2.24M | 2.35M | 6.86M | 10.42M | 10.39M | 10.24M | 10.29M | 1.08M |
Basic Shares Outstanding | 1.29M | 1.71M | 1.19M | 5.92M | 10.42M | 10.39M | 10.24M | 10.29M | 1.08M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
BNR Balance Sheet
Burning Rock Biotech Limited (BNR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 298.93M | 292.99M | 706.79M | 2.52B | 1.82B | 1.26B | 884.1M | 776.62M | 739.06M |
Cash & Short-Term Investments | 190M | 130.13M | 408.22M | 2.26B | 1.5B | 905.45M | 615.1M | 519.85M | 481.39M |
Cash Only | 54.79M | 93.34M | 94.23M | 1.9B | 1.43B | 905.45M | 615.1M | 519.85M | 481.39M |
Short-Term Investments | 135.21M | 36.79M | 313.99M | 362.13M | 63.76M | 0 | 0 | 0 | 0 |
Accounts Receivable | 41.23M | 35.52M | 89.73M | 110.75M | 161.43M | 170.23M | 149.61M | 173.45M | 182.03M |
Days Sales Outstanding | 135.38 | 62.07 | 85.81 | 94.03 | 116.02 | 110.32 | 101.61 | 122.73 | 123.14 |
Inventory | 16.8M | 49.05M | 58.12M | 68.02M | 123.21M | 130.32M | 69.02M | 53.76M | 57.01M |
Days Inventory Outstanding | 155.4 | 242.59 | 195.79 | 214.07 | 312.92 | 259.65 | 144.61 | 127.91 | 152.28 |
Other Current Assets | 50.9M | 3.45M | 133.84M | 67.41M | 8.66M | 30.14M | 21.12M | 11.57M | 18.62M |
Total Non-Current Assets | 101.4M | 79.69M | 140.77M | 139.38M | 457.64M | 328.7M | 155.91M | 108.69M | 81.84M |
Property, Plant & Equipment | 60.69M | 69.58M | 89.31M | 111.48M | 406.44M | 300.03M | 144.2M | 100.34M | 73.92M |
Fixed Asset Turnover | 1.83x | 3.00x | 4.27x | 3.86x | 1.25x | 1.88x | 3.73x | 5.14x | 7.30x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 1.82M | 0 | 0 | 0 |
Intangible Assets | 516K | 482K | 343K | 3.46M | 5.15M | 161K | 964K | 421K | 284K |
Long-Term Investments | 37.33M | 1.99M | 40.16M | 1.42M | 910K | 690K | 337K | 0 | 0 |
Other Non-Current Assets | 2.86M | 7.63M | 10.95M | 23.02M | 45.14M | 26M | 10.41M | 7.93M | 7.64M |
Total Assets | 400.33M▲ 0% | 372.67M▼ 6.9% | 847.56M▲ 127.4% | 2.66B▲ 214.2% | 2.28B▼ 14.4% | 1.59B▼ 30.3% | 1.04B▼ 34.5% | 885.3M▼ 14.9% | 820.9M▼ 7.3% |
Asset Turnover | 0.28x | 0.56x | 0.45x | 0.16x | 0.22x | 0.35x | 0.52x | 0.58x | 0.66x |
Asset Growth % | - | -6.91% | 127.43% | 214.2% | -14.44% | -30.33% | -34.49% | -14.87% | -7.28% |
Total Current Liabilities | 78.06M | 284.7M | 164.44M | 241.53M | 372.18M | 411.45M | 263.36M | 266.3M | 247.14M |
Accounts Payable | 0 | 16.27M | 12.35M | 35.48M | 63.08M | 50.95M | 18.06M | 33.75M | 40.77M |
Days Payables Outstanding | - | 80.44 | 41.6 | 111.66 | 160.21 | 101.51 | 37.84 | 80.29 | 108.9 |
Short-Term Debt | 14.88M | 176.27M | 39.5M | 42.06M | 2.37M | 0 | 0 | 0 | 200K |
Deferred Revenue (Current) | 0 | 57.99M | 53.64M | 75.52M | 143.84M | 149.44M | 131.73M | 118.49M | 107.89M |
Other Current Liabilities | 48.92M | 3.13M | 3.08M | 4.76M | 13.17M | 58.58M | 18.95M | 18.1M | 81.52M |
Current Ratio | 3.83x | 1.03x | 4.30x | 10.45x | 4.89x | 3.06x | 3.36x | 2.92x | 2.99x |
Quick Ratio | 3.61x | 0.86x | 3.94x | 10.17x | 4.56x | 2.74x | 3.09x | 2.71x | 2.76x |
Cash Conversion Cycle | - | 224.22 | 240 | 196.43 | 268.73 | 268.46 | 208.37 | 170.35 | 166.52 |
Total Non-Current Liabilities | 153.79M | 691.44M | 1.57B | 491K | 61.09M | 17.68M | 8.23M | 38.18M | 38.16M |
Long-Term Debt | 153.79M | 87.64M | 18.27M | 0 | 0 | 0 | 0 | 0 | 1.7M |
Capital Lease Obligations | 0 | 5.69M | 4.82M | 0 | 49.32M | 13.55M | 3.69M | 27.75M | 24.47M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 596.12M | 1.55B | 228K | 11.78M | 4.12M | 4.54M | 10.43M | 11.98M |
Total Liabilities | 231.85M | 976.14M | 1.74B | 242.02M | 433.28M | 429.13M | 271.59M | 304.48M | 285.29M |
Total Debt | 168.67M | 272.27M | 67.47M | 46.88M | 86.69M | 50.79M | 12.32M | 52.32M | 43.15M |
Net Debt | 113.88M | 178.93M | -26.76M | -1.85B | -1.34B | -854.66M | -602.77M | -467.53M | -438.25M |
Debt / Equity | 1.00x | - | - | 0.02x | 0.05x | 0.04x | 0.02x | 0.09x | 0.08x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Interest Coverage | -12.26x | -8.89x | -17.82x | -609.55x | -517.10x | - | - | - | -1792.00x |
Total Equity | 168.49M▲ 0% | -603.46M▼ 458.2% | -891.49M▼ 47.7% | 2.42B▲ 371.6% | 1.85B▼ 23.8% | 1.16B▼ 37.2% | 768.41M▼ 33.7% | 580.83M▼ 24.4% | 535.6M▼ 7.8% |
Equity Growth % | - | -458.17% | -47.73% | 371.57% | -23.78% | -37.23% | -33.66% | -24.41% | -7.79% |
Book Value per Share | 93.14 | -269.66 | -379.62 | 352.74 | 177.08 | 111.48 | 75.04 | 56.43 | 496.62 |
Total Shareholders' Equity | 168.49M | -603.46M | -891.49M | 2.42B | 1.85B | 1.16B | 768.41M | 580.83M | 535.6M |
Common Stock | 28K | 29K | 31K | 137K | 137K | 138K | 137K | 145K | 141.09K |
Retained Earnings | -379.52M | -612M | -946.46M | -1.42B | -2.23B | -3.2B | -3.85B | -4.2B | -4.26B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | -58.92M | -65.9M | -63.26M | -57.23M |
Accumulated OCI | -10.88M | -14.8M | 9.3M | -167.59M | -207.07M | -165.72M | -161.53M | -158.05M | -162.24M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BNR Cash Flow Statement
Burning Rock Biotech Limited (BNR) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -133.7M | -148.78M | -228.04M | -73.54M | -477.89M | -456.81M | -255.78M | -92.26M | -28.44M |
Operating CF Margin % | -120.27% | -71.23% | -59.75% | -17.11% | -94.1% | -81.1% | -47.59% | -17.89% | -5.27% |
Operating CF Growth % | - | -11.28% | -53.27% | 67.75% | -549.8% | 4.41% | 44.01% | 63.93% | 69.17% |
Net Income | -131.28M | -177.5M | -169.16M | -407.24M | -796.7M | -971.23M | -653.69M | -346.63M | -55.35M |
Depreciation & Amortization | 21.31M | 24.68M | 31.36M | 33.31M | 47.77M | 124.1M | 133.4M | 52.2M | 21.76M |
Stock-Based Compensation | 4.05M | 5.09M | 22.79M | 173.22M | 282.43M | 326.78M | 260.72M | 155.62M | 13.88M |
Deferred Taxes | 1.16M | 1.37M | 15.62M | 0 | 15.39M | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 5.84M | 3.74M | 1.81M | 15.07M | 35.61M | 74.7M | 55.94M | 83.08M | 50.65M |
Working Capital Changes | -34.79M | -6.16M | -130.46M | 112.1M | -62.4M | -11.16M | -52.16M | -36.53M | -59.39M |
Change in Receivables | -31.16M | 4.16M | -65.95M | -13.04M | -18.93M | -42.16M | -12.39M | -26.8M | -33.23M |
Change in Inventory | -489K | -32.25M | -8.12M | -9.44M | -67M | -21.65M | 57.28M | 2.51M | 2.5M |
Change in Payables | 9.57M | 2.2M | -3.32M | 25.84M | -5.1M | 16.63M | -31.12M | 18.89M | 7.18M |
Cash from Investing | -191.08M | 106.09M | -346.66M | -109.31M | 81.7M | -7.46M | -9.3M | -4.41M | -4.39M |
Capital Expenditures | -23.01M | -24.71M | -45.73M | -79.54M | -213.45M | -62.03M | -8.1M | -5.42M | -5.25M |
CapEx % of Revenue | 20.7% | 11.83% | 11.98% | 18.5% | 42.03% | 11.01% | 1.51% | 1.05% | 0.97% |
Acquisitions | -2.37M | 0 | 401K | 3.97M | 2.53M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -557K | 122K | -303K | -3.32M | -1.96M | -11.03M | -1.2M | 1.01M | 858K |
Cash from Financing | 354.17M | 83.39M | 571.74M | 2.17B | -52.9M | -86.24M | -48.83M | -72K | 1.9M |
Debt Issued (Net) | 11.45M | 82.89M | -81.6M | -20.59M | -44.81M | -2.37M | 0 | 0 | 1.9M |
Equity Issued (Net) | 342.72M | 500K | 653.33M | 2.12B | -4.27M | -71.83M | -6.98M | -72K | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -9.06M | -1.5M | -3.64M | 0 | -4.27M | -71.83M | -6.98M | -72K | 0 |
Other Financing | 0 | 0 | 0 | 67.96M | -3.82M | -12.03M | -41.85M | 0 | 0 |
Net Change in Cash | 17.98M▲ 0% | 40.55M▲ 125.5% | 2.91M▼ 92.8% | 1.83B▲ 62682.2% | -486.09M▼ 126.6% | -513.84M▼ 5.7% | -310.05M▲ 39.7% | -93.05M▲ 70.0% | -41.07M▲ 55.9% |
Free Cash Flow | -156.72M▲ 0% | -173.5M▼ 10.7% | -273.77M▼ 57.8% | -153.08M▲ 44.1% | -691.33M▼ 351.6% | -518.84M▲ 25.0% | -265.17M▲ 48.9% | -98.24M▲ 63.0% | -33.69M▲ 65.7% |
FCF Margin % | -140.97% | -83.06% | -71.73% | -35.61% | -136.13% | -92.12% | -49.34% | -19.04% | -6.24% |
FCF Growth % | - | -10.71% | -57.8% | 44.08% | -351.61% | 24.95% | 48.89% | 62.95% | 65.7% |
FCF per Share | -86.64 | -77.53 | -116.58 | -22.30 | -66.34 | -49.93 | -25.90 | -9.54 | -31.24 |
FCF Conversion (FCF/Net Income) | 1.02x | 0.84x | 1.35x | 0.18x | 0.60x | 0.47x | 0.39x | 0.27x | 0.51x |
Interest Paid | 0 | 0 | 0 | 0 | 1.52M | 877K | 0 | 0 | 30K |
Taxes Paid | 0 | 0 | 0 | 0 | 1.1M | 98K | 0 | 0 | 0 |
BNR Key Ratios
Burning Rock Biotech Limited (BNR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -77.91% | - | - | -53.25% | -37.35% | -64.67% | -67.85% | -51.38% | -9.91% |
Return on Invested Capital (ROIC) | - | - | - | - | -111.4% | -182.83% | -213.92% | -192.28% | -39.05% |
Gross Margin | 64.49% | 64.66% | 71.61% | 73.02% | 71.7% | 67.47% | 67.59% | 70.26% | 74.67% |
Net Margin | -118.09% | -84.98% | -44.1% | -94.73% | -156.87% | -172.44% | -121.63% | -67.2% | -10.26% |
Debt / Equity | 1.00x | - | - | 0.02x | 0.05x | 0.04x | 0.02x | 0.09x | 0.08x |
Interest Coverage | -12.26x | -8.89x | -17.82x | -609.55x | -517.10x | - | - | - | -1792.00x |
FCF Conversion | 1.02x | 0.84x | 1.35x | 0.18x | 0.60x | 0.47x | 0.39x | 0.27x | 0.51x |
Revenue Growth | - | 87.89% | 82.74% | 12.64% | 18.13% | 10.9% | -4.58% | -4.02% | 4.6% |
Related:BNR Dividend History·BNR Revenue History·BNR Price History·BNR P/E History·BNR Financial Ratios·BNR Institutional Holders
BNR Frequently Asked Questions
Burning Rock Biotech Limited (BNR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Burning Rock Biotech Limited (BNR) reported $539.6M in revenue for fiscal year 2025. This represents a 385% increase from $111.2M in 2017.
Burning Rock Biotech Limited (BNR) grew revenue by 4.6% over the past year. Growth has been modest.
Burning Rock Biotech Limited (BNR) reported a net loss of $55.3M for fiscal year 2025.
Dividend & Returns
Burning Rock Biotech Limited (BNR) has a return on equity (ROE) of -9.9%. Negative ROE indicates the company is unprofitable.
Burning Rock Biotech Limited (BNR) had negative free cash flow of $33.7M in fiscal year 2025, likely due to heavy capital investments.